A Russian-made drug Favipiravir that can eliminate
coronavirus infections within four days, is now in the final stages of clinical
trials.
The drug known as Favipiravir is being tested by Russian
pharmaceutical investment firm ChemRar with the support of the Russian Direct
Investment Fund (RDIF).
On Thursday, clinical trials moved to the final stage in
which it is tested on a randomised sample of COVID-19 patients.
The drug has several advantages. One of them is that it
significantly reduces patient recovery time.
Another advantage is its availability in tablet form.
This makes its use easier, according to a statement from the
RDIF.
“We noticed a faster improvement in the general health and
clinical condition of the patients taking Favipiravir”, said said Elena
Yakubova, CEO of ChemRar Pharma in a statement.
“This may lead to earlier discharge from hospital and reduce
the burden on medical facilities by 30-40 percent in the near future,” she
added.
The final stage of trials were approved to begin on May 21,
involving 330 patients, the statement said.
Earlier results had suggested that the drug has no new or
previously unreported side effects and brought down the body temperature of a
majority, 68 percent, of patients twice as fast as patients not taking
favipiravir.
Complete elimination of the coronavirus took on average
around four days with the drug, compared to around nine days with standard
treatment.
“Thanks to the administration of Favipiravir, most patients
are not infectious as early as the fifth day of treatment, which is critical to
stop the epidemic and ensure a swift return to normal life,” Yakubova added.
After four days of treatment with the drug, 65 percent of a
test group of 40 patients were found to test negative for the virus. By day 10,
the number of patients testing negative had reached 35.
“We continue to receive promising data during the clinical trials
of Favipiravir.
“At least 85 percent of patients in the control groups
completely recovered from coronavirus within 10 days after the start of the
treatment with the drug.
“We expect a positive final result of the trial, which will
enable us to complete the registration procedure for the drug in Russia,”
RDIF’S CEO Kirill Dmitriev said in the statement.
Various drugs across the globe are currently undergoing
rapid testing to combat the coronavirus pandemic, which as claimed over 300,000
lives worldwide.
In the US, drugs including remdesivir and famotidine have
shown positive results.
A combination of triple antiviral medicine was recently
shown to help relieve symptoms of patients in a small clinical trial in Hong
Kong.
Reported by Alarabiya
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com